Based on targeted product profile assessments, physicians project notable uptake following approval, with use concentrated among DM patients in need of durable, steroid-sparing efficacy. Beyond ...
6don MSN
Roivant’s Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints
Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best stocks to buy under $20. On September 17, Roivant and Priovant Therapeutics announced positive results from the Phase 3 VALOR study, a 52-week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback